Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Независимый исследователь в области психофармакологии, Израиль, Азур 5801726, ул. Бен-Гурион 26/7; 2 ФГБОУ «Ставропольский государственный медицинский университет», Российская Федерация, г. Ставрополь, 355017, ул. Мира, 310.
Список исп. литературыСкрыть список 1. Adler LA, Edson R, Lavori P et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry. 1998;43:868–872. 2. Adler LA, Rotrosen J, Edson R et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry. 1999;56: 836–841. 3. Alabed S, Latifeh Y, Mohammad HA et al. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018;4:CD000203. 4. Anderson KE, Stamler D, Davis MD et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 2017;4:595–604. 5. Angus S, Sugars J, Boltezar R et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17(2):88–91. 6. Barnes TR, Kidger T. Clonazepam and tardive dyskinesia. Am J Psychiatry 1981;138:1127–1128. 7. Beckmann YY, Secil Y, Saka S et al. Treatment of intractable tardive lingual dyskinesia with botulinum toxin. J Clin Psychopharmacol. 2011;31(2): 250–251. 8. Bergman J, Dwolatzky T, Brettholz I, Lerner V. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry. 2005;66(1):107–110. 9. Bhidayasiri R, Fahn S, Weiner WJ et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–469. 10. Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138:189–193. 11. Boomershine KH, Shelton PS, Boomershine JE. Vitamin E in the treatment of tardive dyskinesia. Ann Pharmacother. 1999;33:1195–1202. 12. Busanello A, Barbosa NB, Peroza LR et al. Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav Pharmacol. 2011;22:71–75. 13. Busanello A, Peroza LR, Wagner C et al. Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol Biochem Behav. 2012;101:307–310. 14. Castro F, Carrizo E, Prieto de, Rincon D et al. Effectiveness of melatonin in tardive dyskinesia. Invest Clin. 2011;52(3):252–260. 15. Chaudhry R, Radonjic D, Waters B. Efficacy of propranolol in a patient with tardive dyskinesia and extrapyramidal syndrome. Am J Psychiatry. 1982;139(5):674–676. 16. Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-Induced Tardive Dyskinesia: A Review and Update. Ochsner J 2017;17(2):162–174. 17. Correll CU, Josiassen RC, Liang GS et al. Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and mood disorder. Psychopharmacol Bull. 2017;47:53–60. 18. Damier P, Thobois S, Witjas T et al. French Stimulation for Tardive Dyskinesia (STARDYS) Study Group Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007;64(2):170–176. 19. Deutetrabenazine: DrugBank. Alberta, Canada: DrugBank database. https://www.drugbank.ca/drugs/DB12161 (2016). 20. Doo AR, Kim SN, Park JY et al. Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. J Ethnopharmacol. 2010;131:433–442. 21. Dressler D, Oeljeschlager RO, Ruther E. Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord. 1997;12(4):585–587. 22. Eltahawy HA, Feinstein A, Khan F, Saint-Cyr J, Lang AE, Lozano AM. Biltaeral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord. 2004;19(8):969–972. 23. Factor SA, Remington G, Comella CL et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 extension study. J Clin Psychiatry. 2017;78:1344–1350. 24. Factor SA. Management of Tardive Syndrome: Medications and Surgical Treatments. Neurotherapeutics. 2020;17(4):1694–1712. 25. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010. 26. Frangos E, Christodoulides H. Clinical observations of the treatment of tardive dyskinesia with haloperidol. Acta Psychiatr Belg. 1975;75(1):19–32. 27. Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology (Berl). 1985;87(4):480–3. 28. Grigoriadis DE, Smith E, Hoare SJ et al. Pharmacologic characterization of valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017;361:454–461. 29. Han YS, Bastianetto S, Dumont Y, Quirion R. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther. 2006;318:238–245. 30. Hauser RA, Factor SA, Marder SR et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484. 31. Hennings JM, Krause E, Botzel K et al. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1167–1171. 32. Häggström JE, Andersson U, Gunne LM. Bromocriptine in tardive dyskinesia. Pharmacopsychiatria. 1982;15(5):161–163. 33. Iwata Y, Irie S, Uchida H et al. Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. J Neurol Sci. 2012;315:137–140. 34. Josiassen RC, Kane JM, Liang GS, et al. Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017;47: 61–68. 35. Kabes J, Sikora J, Pisvejc J, Hanzlicek L, Skondia V. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. International Pharmacopsychiatry. 1982;17(3):185–192. 36. Kane JM, Correll CU, Liang GS et al. Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder. Psychopharmacol Bull. 2017;47:69–76. 37. Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M, Tardive Dyskinesia Assessment Working G. Revisiting the abnormal involuntary movement scale: proceedings from the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018;79(3). 38. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry. 1972;27(1):95–99. 39. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130(4):479–483. 40. Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21(8):1219–1221. 41. Korsgaard S. Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia. Acta Psychiatrica Scandinavica. 1976;54(1):17–24. 42. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother. 2011;45(4):525–531. 43. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(7):1031–1037. 44. Lieberman JA, Alvir J, Mukherjee S, Kane JM. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry. 1989;46(10):908–913. 45. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996;57:167–173. 46. Luo R, Bozigian H, Jimenez R et al. Single dose and repeat once-daily dose safety, tolerability and pharmacokinetics of valbenazine in healthy male subjects. Psychopharmacol Bull. 2017;47:44–52. 47. McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology. 2003;61(3):419. 48. Meco G, Fabrizio E, Epifanio A, Morgante F, Valente M, Vanacore N et al. Levetiracetam in tardive dyskinesia. Clinical Neuropharmacology. 2006;29(5):265–268. 49. Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systemic review. J Clin Psychiatry. 2012;73(11):1434–1438. 50. Mentzel TQ, van der Snoek R, Lieverse R et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. J Clin Psychiatry. 2018;79:17r11852. 51. Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016;21(S1):13–24. 52. Miodownik C, Cohen H, Kotler M et al. Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah. 2003;142(8–9):592–596. 53. Miyaoka T, Furuya M, Yasuda H et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:761–764. 54. Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PDSG. Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study. Neurology. 2007;68:45–50. 55. Nelson LA, McGuire JM, Hausafus SN. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother. 2003;37:1128–1131. 56. O’Brien CF, Jimenez R, Hauser RA et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687. 57. Pappa S, Tsouli S, Apostolou G et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271–275. 58. Patel RS, Mansuri Z, Motiwala F, Saeed H, Jannareddy N, Patel H, Zafar MK. A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. Ther Adv Psychopharmacol. 2019;9:204512531 9847882. 59. Perenyi A, Farkas A. Propranolol in the treatment of tardive dyskinesia. Biol Psychiatry. 1983;18(3):391–394. 60. Pirazzini M, Rossetto O, Eleopra R et al. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200–235. 61. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther. 2013;7:1329– 1340. 62. Ricciardi L, Pringsheim T, Barnes TE et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry 2019;64(6):388–399. 63. Richardson MA, Bevans M, Weber J, Gonzalez J, Flynn CJ, Amira L. Tardive dyskinesia: A nutritional intervention. Eighth Ann New York State Office of Mental Health Research Conference. Albany, New York: NYS Office of Mental Health; 1995:25. 64. Richardson MA, Bevans ML, Read LL et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am. J. Psychiatry 2003;160:1117–1124. 65. Richardson MA, Bevans ML, Weber JB et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl). 1999;143:358–364. 66. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004;65:92–96. 67. Schrodt GR, Jr, Wright JH, Simpson R, Moore DP, Chase S. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):328–331. 68. Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci. 2014;5:24–29. 69. Shamir E, Barak Y, Shalman I et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58(11):1049–1052. 70. Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. Am J Psychiatry 1992;149:391–393. 71. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001;(4)CD000209. 72. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27:159–169. 73. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215–1238. 74. Takeuchi H, Lee J, Fervaha G et al. Switching to clozapine using immediate versus gradual antipsychotic discontinuation: a pilot, double-blind, randomized controlled trial. J Clin Psychiatry. 2017;78(2):223–228. 75. Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(7):1099–1107. 76. Thai-Cuarto D, O’Brien CF, Jimenez R et al. Cardiovascular profile of valbenazine: analysis of pooled data from three randomized, double-blind, placebo-controlled trials. Drug Saf. 2018;41:429–440. 77. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–451. 78. Vaddadi K, Hakansson K, Clifford J et al. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry 2006;18:133–143. 79. Vaddadi KS, Courtney P, Gilleard CJ et al. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989;27(3):313–323. 80. Vaddadi KS. Essential fatty acids and neuroleptic drug induced tardive dyskinesia: preliminary clinical observations. IRCS Med Sci 1984;12:678–679. 81. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76(7):779–787. 82. Wonodi I et al. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. J Clin Psychopharmacol. 2004;24(4):441–445. 83. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–554. 84. Yahya AS, Khawaja S. Electroconvulsive Therapy as a Treatment for Tardive Dyskinesia. Prim Care Companion CNS Disord. 2021;23(3):20r02775. 85. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615–621. 86. Zheng W, Xiang YQ, Ng CH, Ungvari GS, Chiu HF, Xiang YT. Extract of Ginkgo biloba for tardive dyskinesia: meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2016;49(3):107–111.